Company intelligence / Profile preview
Generation Bio
Cambridge, Massachusetts, United States
- Ownership
- Public · GBIO
- Development stage
- Preclinical
01
Overview
Generation Bio has developed a T cell-selective lipid nanoparticle that achieved approximately 98% knockdown of the B2M protein in human T cells in both in vitro and mouse studies. The company plans to announce its lead target and indication in mid-2025 and submit an IND application in the second half of 2026.[6]
- Therapeutic areas
- Immunology
- Modalities
- siRNA therapeuticsgenetic medicines
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $36M
- Total revenue
- $1.6M
- Enterprise value
- $-27.5M
Beyond the preview
Go deeper on Generation Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Generation Bio.